One-Liner
A consumer subscription alerting rare-disease patients when a newly approved drug becomes relevant to their condition — killed because patient-side budget is too constrained and advocacy nonprofits (NORD, Global Genes) can absorb this as a free feature.
AI Thinking Process
Rare-disease patients wait 8-14 months after FDA approval before their PCP knows to prescribe. Alert service could close this gap.
NORD and Global Genes publish approval calendars free. AllStripes ($75M) is patient data platform, not consumer alert. G163 fires: advocacy nonprofits can add approval-alert toggle in 2 sprints.
G144 (patient budget) + G163 (nonprofit absorbs) + pharma-sponsor pivot = cross-flavor duplicate. Kill.
Kill Reason
G144 buyer-budget mismatch: rare-disease patients typically low-income or on Medicaid; willingness to pay $10/month is low when NORD offers the same for free. G163 nonprofit-absorbs: NORD and Global Genes have patient-registry infrastructure to add approval alerts in 2 sprints. Pharma-sponsor pivot was a cross-flavor duplicate of same-day T10 (IgAN patient finder for sponsors).
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.